CenExel contributed to a new NEJM pain study
The Phase 2b trial evaluated LTG-001, an NaV1.8 inhibitor, and found significant pain reduction versus placebo; the high-dose group also required less opioid rescue.
See the latest news and media coverage for CenExel. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical research site network
cenexelresearch.comLast updated
In short: CenExel appointed a new CFO, was acquired by BayPine, and contributed to the clinical trials leading to the FDA approval of Journavx.
The Phase 2b trial evaluated LTG-001, an NaV1.8 inhibitor, and found significant pain reduction versus placebo; the high-dose group also required less opioid rescue.
Bethany Sensenig will oversee financial strategy, planning, and accounting as CFO, bringing nearly three decades of biopharmaceutical executive experience.
Nearly 80% of non-US raters experience burnout, impacting data quality. Presented at ASCP meeting.
The EMERGENT-3 trial met its primary endpoint with an 8.4-point PANSS reduction versus placebo, supporting a new muscarinic antipsychotic class.
“Finding patients for pharma companies and getting them into the trial as quickly as possible is really a key need that these companies are willing...
BayPine LP (“BayPine”), a private investment firm that drives digital transformation in market-leading businesses, today announced that it has entered into a...
(MENAFN- GlobeNewsWire - Nasdaq) Salt Lake City, UT, July 17, 2023 (GLOBE NEWSWIRE) -- The cenexel Board of Directors is delighted to announce that Stuart...
Salt Lake City, Utah, May 03, 2022 (GLOBE NEWSWIRE) -- CenExel announces the acquisition of iResearch ("CenExel iResearch"), a leading multi-specialty research site business with...
Track CenExel and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.